Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanreqing capsules for mild to moderate acute exacerbation of chronic obstructive pulmonary disease
CTR20254091Phase 3Active
- Sponsor
- Shanghai Kaibao Pharmaceutical
- Start
- Nov 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tanreqing capsules with Placebo (2 arms). Primary endpoint: Change from baseline in BCSS score at Day 7. Started Nov 2025; status: active.
02
Drugs
Tanreqing Capsules
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20254091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254091.